---

MDS: recent advances overview

A. Giagounidis

Therapy of lower risk

R. Latagliata

Therapy of higher risk

V. Santini

Supportive therapy

P. Musto

Timing allografting

M.G. Della Porta

Risk stratification and MRD

N. Russell

Current management in younger adults

A. Venditti

Current management in older patients

A. Isidori

Immunotherapy: where are we now?

A. Curti

Discussion

F. Ciceri

Mouse model of human ALL

G. Inghirami

Management of Ph positive patients

S. Chiaretti

Management of Ph negative patients

R. Bassan

Digital-doplet PCR for MRD monitoring

I. Della Starza

CAR-T and CIK

A. Rambaldi

Stereotyped receptors

P. Baliakas

BCR and cell signaling

P. Ghia

Real life studies

M. Montillo

Guidelines: open issues

S. Molica

Prospects for future improvement

G. Pizzolo

JOHN GOLDMAN LECTURE

M.J. Mauro

ELN guidelines

J. Apperley

The Italian CML registry

G. Specchia / G. Saglio

CML and pregnancy

E. Abruzzese

Treatment discontinuation for CML in clinical practice

C. Fava

New drugs and future combination therapy

M. Breccia

Aggressive non-Hodgkin lymphomas

U. Vitolo

Hodgkin lymphoma

M. Spina

Waldenström macroglobulinemia

A. Tedeschi

Molecular basis

I. Plo

Integrate prognostic score

P. Guglielmelli

Present and future of JAK2 inhibitors

F. Passamonti

Stem cell transplantation in 2019

W. Arcese / R. Cerretti

A critical reappraisal of antithrombotic therapy

V. De Stefano